Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/0019-5154.190107 http://scihub22266oqcxt.onion/10.4103/0019-5154.190107 C5029243/?report=reader!5029243!27688447     free     free     free       Indian+J+Dermatol 2016 ; 61 (5): 550-3 Nephropedia Template TP {{tp|p=27688447|t=2016. Belimumab in Systemic Lupus Erythematosus |pdf=|usr=}}{{27688447}} gab.com Text Belimumab in Systemic Lupus Erythematosus JO: Indian J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=27688447 #FOAvip Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1? monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders. Twit Text FOAVip Belimumab in Systemic Lupus Erythematosus ????Indian J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=27688447 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27688447 #FOAvip English Wikipedia <ref>{{Cite pmid|27688447}}</ref> Belimumab in Systemic Lupus Erythematosus #MMPMID27688447 Srivastava A Indian J Dermatol 2016[Sep]; 61 (5): 550-3 PMID27688447show ga Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1? monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders. äBelimumab in Systemic Lupus Erythematosus (epmc).pdf DeepDyve Pubget Overpricing